Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3

Background and AimRecent studies suggest that the anti-inflammatory agent balsalazide (BSZ) and probiotic agent VSL#3 have potential therapeutic benefits for the treatment of patients with inflammatory bowel disease. However, their effectiveness in preventing colitis-associated carcinogenesis (CAC) remains uncertain. The aim of the present study was to determine the chemopreventive effects of BSZ and VSL#3 in the murine azoxymethane (AOM)/dextran sodium sulfate (DSS) model. MethodsC57B/L6J mice were randomly divided into four groups: CAC group, BSZ group, VSL#3 group, and BSZ+VSL#3 group. After 2weeks, the AOM/DSS model was induced by AOM injection followed by two cycles of 2% DSS. ResultsDuring first and second cycles of DSS, the number of F4/80-positive macrophages was significantly lower in the drug-treated groups compared with the CAC group (P<0.05). At the endpoint, the total numbers of tumors in the drug-treated groups were significantly low compared with the CAC group (P<0.05), and the drug-treated groups had significantly lower F4/80-positive macrophages in the tumor stroma (P<0.01). The protein production of macrophage inflammatory protein 1 beta, monocyte chemoattractant protein-1, interleukin (IL)-6, and IL-10 in the colon tissues decreased in concordance with the plasma concentrations of the cytokines (P<0.05). The drug-treated groups revealed lower expression of p-STAT3 compared with the CAC group. In addition, BCL2 decreased, and BAX increased markedly in the BSZ+VSL#3 group. ConclusionsThese results revealed that BSZ and VSL#3 have chemopreventive effects against CAC through IL-6/STAT3 suppression. BSZ and VSL#3 could be suitable options for chemoprevention of colorectal cancer.